Andrew Abrams has real hands-on science experience, including co-authoring a research paper on DNA-end processing machinery, and earned First Class Honours as a Richard Perham Scholar at Cambridge before spending a year working directly inside New Science Ventures' therapeutics incubator in San Diego. He now serves as a director on the boards of Trellis Bioscience and Vimalan Biosciences and as an observer for Morrow and Novadip, building on an early reputation at J.P. Morgan as one of the firm's strongest analysts.